Clinical trial · Interventional
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
A Phase 1 Study of TAS2940 in Patients With Locally Advanced or Metastatic Solid Tumors With EGFR and / or HER2 Aberrations
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.
Summary
Brief summary (as posted)
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TAS2940 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- TAS2940 Dose Escalation
- description
- Dose escalation will assess the safety and determine the maximum tolerated dose, the recommended phase 2 dose and the recommended dosing regimen of TAS2940 administered orally.
- interventionNames
- Drug: TAS2940
- type
- EXPERIMENTAL
- label
- Dose Expansion Non-small Cell Lung Cancer
- description
- Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
- interventionNames
- Drug: TAS2940
- type
- EXPERIMENTAL
- label
- Dose Expansion Breast Cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted * Have adequate organ function * ECOG PS 0-1 Dose Escalation: * Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO * Any solid tumor with EGFR and / or HER2 aberration Dose Expansion: * Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma) * Cohort A: Non-small cell lung cancer (NSCLC) * Cohort B: HER2 positive breast cancer * Cohort C: Recurrent or refractory glioblastoma * Cohort D: Other solid tumors with EGFR or HER2 aberrations Exclusion Criteria: * Non-stable brain metastases * Have significant cardiovascular disorder * Have not recovered from prior cancer treatment * A serious illness or medical condition
References
Publications (0)
Data not yet available